{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:59:06Z","timestamp":1791417546573,"version":"4.3.3"},"reference-count":3,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Omlyclo (omalizumab-igec), the first FDA-approved biosimilar to omalizumab (Xolair) in the United States, was approved on 7 March 2025, for multiple indications including atopic asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria (CSU). Functioning as an anti-IgE monoclonal antibody, Omlyclo binds free IgE, preventing its interaction with Fc\u03b5RI receptors on mast cells and basophils, thereby reducing inflammatory responses. Clinical trials, including a pivotal global Phase 3 study in CSU, demonstrated comparable efficacy to Xolair with a significantly reduced cost, enhancing accessibility for patients. While generally well tolerated, reported side effects include pruritus, vertigo, and gastrointestinal disturbances, with rare concerns regarding malignancy risk requiring further long-term evaluation. The availability of this cost-effective biosimilar marks an important milestone in expanding biologic treatment access for patients with allergic asthma and CSU.<\/jats:p>","DOI":"10.1097\/ms9.0000000000003786","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T15:00:44Z","timestamp":1756738844000},"page":"6890-6891","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Biologic relief without the price tag: the promise of omlcylo in atopic asthma and chronic spontaneous urticaria"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5060-3376","authenticated-orcid":false,"given":"Anna","family":"Mumtaz","sequence":"first","affiliation":[{"name":"Karachi Medical and Dental College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1741-3359","authenticated-orcid":false,"given":"Kamran","family":"Shahid","sequence":"additional","affiliation":[{"name":"Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3413-2752","authenticated-orcid":false,"given":"Maliha","family":"Khalid","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3283-1982","authenticated-orcid":false,"given":"Aminath","family":"Waafira","sequence":"additional","affiliation":[{"name":"The Maldives National University, Mal\u00e9, Maldives"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"R3-20260204","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","article-title":"2023 GINA report for asthma","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R5-20260204","doi-asserted-by":"crossref","first-page":"2392\u2013402","DOI":"10.1016\/j.jaip.2023.01.022","article-title":"Omalizumab in Chronic Spontaneous Urticaria (CSU): real-life experience in dose\/interval adjustments and treatment discontinuation","volume":"11","author":"Br\u00e1s","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R6-20260204","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:03:08Z","timestamp":1770217388000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":3,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003786","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"2025-08-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}